entertainment -WSS

entertainment

author：comprehensive 2025-09-27 23:20:05 - browse：173

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Illumina slashes 2023 revenue projections yet again

Wikipedia

WSS

Novo Nordisk touts Wegovy study, but still struggling with supply

Bird flu researchers hone in on Finland’s mink farms

Mark Cuban is blaming the wrong people for high drug costs

Hospitals are dialing back on venture capital investing

Amazon expands telehealth clinic nationwide

Biden administration begins canceling student loan debt for 804,000 borrowers

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Bright Health sells Medicare Advantage business to Molina

After Optum profits sink, UnitedHealth makes changes

Guidelines to prevent youth baseball injuries need more muscle

Mega Millions pot grows to $1.25 billion after no winner

As demand for Covid shots wanes, Moderna seeks its next success

Scientists inch closer to single

Jerome Adams on the need for new antivirals for Covid

Aspartame and sugar

Walensky prepares to leave CDC — and Congress — behind

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wikipedia

Mega Millions pot grows to $1.25 billion after no winner

Judge sides with young activists in first

5 important ways Henrietta Lacks changed medical science

Novo Nordisk touts Wegovy study, but still struggling with supply

The high personal cost of affirmative action for Black doctors

What the airline industry can learn from medicine

entertainment

explore

Wikipedia

focus